Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1197395 | 0.91 | KDM4E (0.57) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1197661 | 0.90 | KDM4E (0.55) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1198545 | 0.90 | KDM4E (0.55) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1198481 | 0.87 | KDM4E (0.63) | KDM4EALDH1A1MEN1KMT2AITGB3 | |
| SCHEMBL1198785 | 0.84 | MEN1 (0.68) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1198576 | 0.81 | KDM4E (0.83) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1198154 | 0.79 | KDM4E (0.62) | KDM4EALDH1A1MEN1KMT2AITGB3 | |
| SCHEMBL28787228 | 0.79 | KDM4E (0.60) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL27806760 | 0.79 | MEN1 (0.62) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1198516 | 0.78 | KDM4E (0.61) | KDM4EALDH1A1MEN1KMT2AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| CN-102056907-A | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2011-05-11 | — | — | CN | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009123316-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | 武田薬品工業株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | KDM4E 1877/4885ALDH1A1 1037/4885RAB9A 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.